Second Alzheimer's drug to slow disease's progression may be approved in the US this year

A second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug Administration submission for the drug, and expects regulatory action by year’s end.

Related Keywords

Wisconsin ,United States ,California ,San Francisco ,American ,Americans ,Eric Widera ,Sharon Brangman ,Lawrence Honig ,Joe Montminy ,Los Angeles ,Gil Rabinovici ,Nathaniel Chin ,Eli Lilly ,Daniel Skovronsky ,University Dr ,Drug Administration ,Columbia University Irving Medical Center ,University Of Wisconsin Dr ,Journal Of The American Medical Association ,University Of California ,Alzheimer Association International Conference On ,Cnn ,Association International Conference ,American Medical Association ,Kacie Deters ,Disease Rating Scale ,Clinical Dementia Rating Sum ,Medical University , ,